

L12 ANSWER 4 OF 7 MEDLINE
 ACCESSION NUMBER: 94295910 MEDLINE
 DOCUMENT NUMBER: 94295910 PubMed ID: 8024121
 TITLE: Stabilization of the peptide conformation on the micellar surface.
 AUTHOR: Shapiro YuE; Gorbatyuk VYa; Mazurov A A; Andronati S A
 CORPORATE SOURCE: A. V. Bogatsky Physico-Chemical Institute, Ukrainian Academy of Sciences, Odessa.
 SOURCE: ANALYST, (1994 Apr) 119 (4) 647-52.
 Journal code: 4OS; 0372652. ISSN: 0003-2654.
 PUB. COUNTRY: ENGLAND: United Kingdom
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199408
 ENTRY DATE: Entered STN: 19940815
 Last Updated on STN: 19960129
 Entered Medline: 19940802

AB The conformational mobility of peptide molecules plays a significant role in peptide-receptor interactions and quantitative structure-activity relationships. As a receptor mimetic system, bis(2-ethylhexyl) sodium succinate (AOT) reversed **micelles** containing an aqueous solution of one of the melanotrophine inhibiting factor analogues prolyltyrosyl-glycinamide hydrochloride in the inner cavity have been used. **Two-dimensional nuclear magnetic resonance** spectroscopy (NOESY) and ¹³C spin-lattice relaxation time measurements have been used to establish that the peptide molecule assumes the biologically active beta II turn conformation when it is adsorbed at the surfactant-water border. This conformation is stabilized by intramolecular H-bonding between the proline carbonyl oxygen atom and amide protons. Moreover, it has been shown that the phenyl ring of tyrosine was inserted into the AOT intermolecular cavity, which is located between the polar AOT groups and the branches of iso-octane fragments. By and large, the phenyl ring acts as a hydrophobic anchor. Reversed **micelles** can be regarded as providing a realistic model of the receptor.

RESULT 4

P70270

ID P70270 standard; protein; 227 AA.

XX

AC P70270;

XX

DT 27-FEB-1991 (first entry)

XX

DE The sequence encoding the HIV virus 24 KDa gag precursor protein.

XX

KW HIV virus; gag protein; AIDS; vaccine.

XX

OS HIV virus.

XX

PN EP230222-A.

XX

PD 29-JUL-1987.

XX

PF 05-JAN-1987; 87EP-0100064.

XX

PR 06-JAN-1986; 86US-0816645.

XX

PA (HOFF) HOFFMANN-LA ROCHE AG.

XX

PI Kramer R, Reddy P, Shaber M;

XX

DR WPI; 1987-207550/30.

DR

N-PSDB; N70429.

XX

PT Polypeptide obtd. from HTLV-III gag-gene - used for detecting
PT AIDS virus and for prepn. of vaccines giving protective immunity.

XX

PS Claim 6; Page 13; 39pp; English.

XX

CC The sequence encodes the HIV virus 24KDa gag precursor protein.

CC

The HIV virus gag protein or proteolytically derived products

CC

may be used as a vaccine against HIV virus infection (AIDS).

CC

See also N70427, N70428, N70430, N70431 and N70432.

XX

SQ Sequence 227 AA;

Query Match 97.1%; Score 170; DB 8; Length 227;

Best Local Similarity 100.0%; Pred. No. 2.1e-19;

Matches 32; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NPPIPVGGEIYKRWIIILGLNKIVRMYSPTSILD 32

Db 121 nppipvgelykrwiiilglnkivrmysptsild 152

L16 ANSWER 9 OF 10 MEDLINE

ACCESSION NUMBER: 78131443 MEDLINE

DOCUMENT NUMBER: 78131443 PubMed ID: 344799

TITLE: Enhancement of carrier-specific helper T cell function by the synthetic adjuvant, N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP).

AUTHOR: Sugimoto M; Germain R N; Chedid L; Benacerraf B

SOURCE: JOURNAL OF IMMUNOLOGY, (1978 Mar) 120 (3) 980-2.

Journal code: IFB; 2985117R. ISSN: 0022-1767.

PUB. COUNTRY: United States

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 197805

ENTRY DATE: Entered STN: 19900314

Last Updated on STN: 19900314

Entered Medline: 19780517

AB The adjuvant effect of a synthetic peptidoglycan, muramyl dipeptide (N-acetyl muramyl-L-alanyl-D-isoglutamine, MDP), was studied by using the anti-Tnp PFC and **hemagglutinin** responses of BALB/c mice to hapten-carrier conjugates. Administration of Tnp-OVA and MDP in saline to mice, followed 2 weeks later by a boost of Tnp-OVA in saline, led to significantly higher IgM and IgG anti-Tnp PFC and total anti-Tnp-**hemagglutinin** responses than those obtained in mice not treated with MDP in the initial immunization. A similar adjuvant effect by MDP on anti-hapten PFC responses was seen if mice were primed with **KLH** together with MDP and challenged with Tnp-**KLH** 2 weeks later. This apparent effect on carrier priming for helper function was confirmed and quantitated by double adoptive transfer experiments with graded numbers of spleen cells from **KLH** +/- MDP-primed mice and a fixed number of hapten-primed spleen cells from syngeneic Tnp-OVA immunized animals. These data suggest that at least one mode of action of the synthetic adjuvant MDP is via the enhanced stimulation of the helper T cell function.

FILE 'MEDLINE' ENTERED AT 11:51:50 ON 26 JUN 2001

L1	36053 S TWO DIMENTIONAL NUCLEAR MAGNETIC RESONANCE OR NMR
L2	6595 S MICELLE?
L3	606 S L1 AND L2
L4	288047 S REVIEW
L5	4 S L3 AND L4
L6	291081 S PEPTIDE?
L7	247 S L6 AND L3
L8	100156 S HIV
L9	8 S L7 AND L8
L10	0 S TWO DIMENTIONAL NUCLEAR MAGNETIC RESONANCE
L11	312 S TWO DIMENSIONAL NUCLEAR MAGNETIC RESONANCE
L12	7 S L11 AND L2

FILE 'MEDLINE' ENTERED AT 09:05:25 ON 26 JUN 2001

L1	6595 S MICELLE?
L2	19935 S ACETIC ACID
L3	14 S L1 AND L2
L4	14 DUP REM L3 (0 DUPLICATES REMOVED)
L5	36073 S NMR OR NUCLEAR MAGNETIC IMAGING
L6	14 S L4
L7	2 S L4 AND L5
L8	255 S KLH AND HA
L9	288047 S REVIEW
L10	4 S L8 AND L9
L11	2788 S KEYHOLE LIMPET OR KLH
L12	1169419 S HEMAGGLUTININ OR HA
L13	489 S L11 AND L12
L14	7 S L13 AND L9
L15	10593 S HEMAGGLUTININ
L16	10 S L15 AND L11